[go: up one dir, main page]

MX2019000384A - Metodo para producir una forma polimorfica de 3-[5-amino-4-(3-cianobenzoilo)-pirazol-1-il]-n-ciclopropil-4-meti lbenzamida. - Google Patents

Metodo para producir una forma polimorfica de 3-[5-amino-4-(3-cianobenzoilo)-pirazol-1-il]-n-ciclopropil-4-meti lbenzamida.

Info

Publication number
MX2019000384A
MX2019000384A MX2019000384A MX2019000384A MX2019000384A MX 2019000384 A MX2019000384 A MX 2019000384A MX 2019000384 A MX2019000384 A MX 2019000384A MX 2019000384 A MX2019000384 A MX 2019000384A MX 2019000384 A MX2019000384 A MX 2019000384A
Authority
MX
Mexico
Prior art keywords
pyrazol
amino
methylbenzamide
cyclopropyl
cyanob
Prior art date
Application number
MX2019000384A
Other languages
English (en)
Other versions
MX379452B (es
Inventor
Suleiman Osama
Romero Perez Lucia
Stephan Harlacher Cornelius
Jones Stewart
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of MX2019000384A publication Critical patent/MX2019000384A/es
Publication of MX379452B publication Critical patent/MX379452B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a un proceso para la preparación de la Forma B de 3-[5-amino-4-(3-cianobenzoil)pirazol-1-iI]-N-ciclopropi l-4-metilbenzamida. En la presente también se describe la Forma B de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-met ilbenzamida, o composiciones farmacéuticas de la misma, que se pueden obtener mediante el procedimiento descrito en la presente.
MX2019000384A 2016-07-14 2017-07-13 Método para producir una forma polimórfica de 3-[5-amino-4-(3-cianobenzoilo)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida. MX379452B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1612238.4A GB201612238D0 (en) 2016-07-14 2016-07-14 Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
PCT/GB2017/052055 WO2018011578A1 (en) 2016-07-14 2017-07-13 Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide

Publications (2)

Publication Number Publication Date
MX2019000384A true MX2019000384A (es) 2019-05-23
MX379452B MX379452B (es) 2025-03-10

Family

ID=56890595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000384A MX379452B (es) 2016-07-14 2017-07-13 Método para producir una forma polimórfica de 3-[5-amino-4-(3-cianobenzoilo)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida.

Country Status (18)

Country Link
US (1) US10995071B2 (es)
EP (1) EP3484853B9 (es)
JP (1) JP7094020B2 (es)
KR (1) KR102460533B1 (es)
CN (1) CN109415325B (es)
AU (1) AU2017294642B2 (es)
CA (1) CA3030617C (es)
DK (1) DK3484853T5 (es)
ES (1) ES2879608T3 (es)
GB (1) GB201612238D0 (es)
HU (1) HUE054686T2 (es)
IL (1) IL263900B (es)
MX (1) MX379452B (es)
PL (1) PL3484853T3 (es)
PT (1) PT3484853T (es)
RU (1) RU2765719C2 (es)
SG (1) SG11201811517SA (es)
WO (1) WO2018011578A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100404256B1 (ko) 1998-05-05 2003-11-01 에프. 호프만-라 로슈 아게 피-38 엠에이피 키나제 저해제로서의 피라졸 유도체
PT1641764E (pt) 2003-06-26 2011-10-27 Novartis Ag Inibidores de p38 quinase a base de heterociclo de 5 elementos
AU2013237503B2 (en) 2012-03-20 2016-05-26 Mereo Biopharma 1 Limited Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR20180119597A (ko) 2016-03-08 2018-11-02 메레오 바이오파마 1 리미티드 염증 상태의 급성 악화의 치료를 위한 투약법
CA3016488C (en) 2016-03-08 2023-04-11 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
KR102460533B1 (ko) 2022-10-31
AU2017294642A1 (en) 2019-01-17
WO2018011578A1 (en) 2018-01-18
RU2019103879A (ru) 2020-08-14
CA3030617A1 (en) 2018-01-18
JP2019521133A (ja) 2019-07-25
IL263900A (en) 2019-01-31
RU2765719C2 (ru) 2022-02-02
RU2019103879A3 (es) 2020-08-14
US10995071B2 (en) 2021-05-04
PL3484853T3 (pl) 2021-11-02
KR20190027819A (ko) 2019-03-15
CN109415325B (zh) 2022-04-01
EP3484853A1 (en) 2019-05-22
BR112019000540A2 (pt) 2019-04-24
AU2017294642B2 (en) 2021-03-04
IL263900B (en) 2022-04-01
SG11201811517SA (en) 2019-01-30
JP7094020B2 (ja) 2022-07-01
CN109415325A (zh) 2019-03-01
DK3484853T5 (da) 2021-09-06
ES2879608T3 (es) 2021-11-22
EP3484853B1 (en) 2021-04-21
MX379452B (es) 2025-03-10
HUE054686T2 (hu) 2021-09-28
DK3484853T3 (da) 2021-05-25
EP3484853B9 (en) 2021-07-28
GB201612238D0 (en) 2016-08-31
US20190315694A1 (en) 2019-10-17
PT3484853T (pt) 2021-05-25
CA3030617C (en) 2024-02-20

Similar Documents

Publication Publication Date Title
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
CL2020002277A1 (es) Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734)
AR103992A1 (es) Método para preparar compuestos fenólicos a partir de biomasa
BR112017025873A2 (pt) método para revestir a cabeça de um pirulito com um material de revestimento
MX2020008507A (es) Metodo para producir 1,1,3,3-tetracloropropeno.
MX391448B (es) Metodo para producir esteres de tetrahidropiranilo.
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
MX2015015151A (es) Metodo para producir 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos, donde dicho proceso usa reciclado.
PL3445739T3 (pl) Proces destylacji mieszaniny aldehydów
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
HUE070866T2 (hu) Eljárás kalcium-magnézium-szulfonát kenõzsírok elõállítására
ES2670477R1 (es) Procedimiento para la preparacion de la 17beta-hidroxi-des-a-androst-9,10-en-5-ona
MX389640B (es) Método para producir dipropionato de calcio.
MX382659B (es) Proceso para la preparación de derivados de tiazol.
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
IT201800011142A1 (it) Forma per la produzione di calzature
BR112018069255A2 (pt) processos para a preparação de ácidos heteroaril carboxílicos
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
MX2016007864A (es) Control de la formacion de cuerpos de color en la esterificacion de isohexida.
BR112016030705B8 (pt) Lipídeo de planta extraído e composição compreendendo o referido lipídeo
MX2019000384A (es) Metodo para producir una forma polimorfica de 3-[5-amino-4-(3-cianobenzoilo)-pirazol-1-il]-n-ciclopropil-4-meti lbenzamida.
BR112019000460A2 (pt) método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il] -n-ciclopropil-4-metilbenzamida